CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN) Abstract #1714

Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.
Aim(s): CALM-NET (NCT02075606) investigates the benefit of enumerating CTCs to predict symptom control in midgut NET pts on LAN.
Materials and methods: This study enrolled 50 pts with somatostatin receptor positive, functioning midgut G1/G2 NET. Pts were not permitted to receive interferon, chemotherapy, chemoembolisation or radionuclide therapy within 3 mo of study entry; prior somatostatin analogue treatment was permitted but after washout. Pts receive LAN at a starting dose of 120mg/28d; after 3 injections, dose can be maintained or down-titrated to 60 or 90mg/28d for remainder of the study. CTC levels are measured at 1, 5, 17, 25 & 53wks, and pts report on symptom control. Frequency/severity of symptoms are taken daily in the first 16wks, on days 11-17 for subsequent injections and days 11-28 after wk49. CT/MRI scans are used to assess progression at wks25 & 53. Impact on quality of life is assessed via the EORTC QLQ-NET21 and QLQ-C30.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Kate Higgs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy
Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Yong-Il Kim
#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs
Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD Barbara Kiesewetter
#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors
Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Prof Rachel Riechelmann